Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

CNTY-101

Cell therapy (NK cells) · Kills target cells, directed at CD19 · developed by Century Therapeutics

Phase 1 Most advanced trial
IPSC Developer
1 Registered trials

What is CNTY-101?

CNTY-101 is an allogeneic natural killer cell preparation derived from a clonal induced pluripotent stem cell line and engineered to express an anti-CD19 chimeric antigen receptor and IL-15. The cells recognize and kill CD19-expressing cells and carry an EGFR-based safety switch that allows their elimination with anti-EGFR antibodies such as cetuximab. It is being studied in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathies and diffuse cutaneous systemic sclerosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
cytotoxicity against CD19-expressing cells, T-cell persistence
Therapy area
Immunology, Renal & urology
Developer
Century Therapeutics, Inc. (IPSC)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06255028 Phase 1 Systemic Lupus Erythematosus Active not recruiting IPSC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diffuse Cutaneous Systemic SclerosisIdiopathic Inflammatory MyopathiesLupus NephritisSystemic Lupus Erythematosus

Other drugs acting on CD19

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPSC page.

Follow IPSC, the company behind CNTY-101

See IPSC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPSC catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.